Shares of Repligen Co. (NASDAQ:RGEN) gapped up prior to trading on Tuesday . The stock had previously closed at $208.11, but opened at $214.85. Repligen shares last traded at $203.82, with a volume of 2,396 shares traded.
Several equities research analysts have weighed in on the company. Craig Hallum upped their target price on Repligen from $245.00 to $251.00 and gave the stock a “buy” rating in a report on Thursday, February 25th. HC Wainwright reissued a “buy” rating and issued a $225.00 price target (up from $168.00) on shares of Repligen in a research report on Monday, April 19th. Zacks Investment Research lowered Repligen from a “strong-buy” rating to a “hold” rating and set a $200.00 target price on the stock. in a research report on Tuesday, January 5th. Finally, SVB Leerink upped their target price on Repligen from $220.00 to $250.00 and gave the company an “outperform” rating in a research report on Wednesday, March 3rd. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Repligen has a consensus rating of “Buy” and an average target price of $215.20.
The firm has a fifty day moving average of $204.37 and a 200 day moving average of $198.75. The company has a debt-to-equity ratio of 0.21, a current ratio of 13.67 and a quick ratio of 12.13. The stock has a market cap of $11.05 billion, a price-to-earnings ratio of 253.07, a PEG ratio of 4.18 and a beta of 0.94.
In other Repligen news, Director Thomas F. Ryan, Jr. sold 1,000 shares of the firm’s stock in a transaction on Wednesday, March 3rd. The stock was sold at an average price of $205.00, for a total value of $205,000.00. Following the sale, the director now directly owns 2,464 shares in the company, valued at $505,120. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP James Bylund sold 360 shares of the firm’s stock in a transaction on Tuesday, April 6th. The shares were sold at an average price of $204.25, for a total value of $73,530.00. Following the completion of the sale, the senior vice president now owns 6,324 shares in the company, valued at $1,291,677. The disclosure for this sale can be found here. Over the last quarter, insiders sold 47,382 shares of company stock valued at $9,056,388. 1.70% of the stock is currently owned by company insiders.
A number of institutional investors have recently bought and sold shares of RGEN. Amundi Pioneer Asset Management Inc. acquired a new stake in Repligen in the first quarter valued at $2,925,000. Brinker Capital Investments LLC acquired a new position in Repligen in the 3rd quarter valued at about $221,000. Sei Investments Co. increased its position in Repligen by 66.7% in the 3rd quarter. Sei Investments Co. now owns 16,172 shares of the biotechnology company’s stock valued at $2,382,000 after acquiring an additional 6,472 shares during the period. Mercer Global Advisors Inc. ADV increased its position in Repligen by 6.4% in the 3rd quarter. Mercer Global Advisors Inc. ADV now owns 3,471 shares of the biotechnology company’s stock valued at $512,000 after acquiring an additional 209 shares during the period. Finally, HM Payson & Co. acquired a new position in Repligen in the 3rd quarter valued at about $40,000. Institutional investors own 84.33% of the company’s stock.
About Repligen (NASDAQ:RGEN)
Repligen Corp. provides bioprocessing technologies and solutions used in the process of manufacturing biologic drugs. It serves through the following product lines: Chromatography, Filtration and OEM Products (Proteins). The Chromatography product line includes a number of products used in the downstream purification and quality control of biological drugs.
Read More: Equal Weight Rating
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.